ARTICLE | Company News
AstraZeneca in-licenses Merck cancer compound
September 12, 2013 12:25 AM UTC
Merck & Co. Inc. (NYSE:MRK) granted AstraZeneca plc (LSE:AZN; NYSE:AZN) exclusive, worldwide rights to develop and commercialize MK-1775. Merck will receive $50 million up front and is eligible for un...